Nabriva Therapeutics (NASDAQ:NBRV) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV) in a report released on Wednesday morning. The firm issued a hold rating on the biotechnology company’s stock.

Nabriva Therapeutics Stock Performance

The business’s 50-day moving average price is $0.14 and its 200-day moving average price is $0.61. The stock has a market cap of $45.46 million, a PE ratio of -0.07 and a beta of 1.53. Nabriva Therapeutics has a fifty-two week low of $1.22 and a fifty-two week high of $8.45. The company has a quick ratio of 0.52, a current ratio of 0.85 and a debt-to-equity ratio of 0.12.

Institutional Investors Weigh In On Nabriva Therapeutics

An institutional investor recently raised its position in Nabriva Therapeutics stock. Renaissance Technologies LLC boosted its stake in Nabriva Therapeutics plc (NASDAQ:NBRV) by 102.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 795,938 shares of the biotechnology company’s stock after purchasing an additional 402,144 shares during the period. Renaissance Technologies LLC owned approximately 0.13% of Nabriva Therapeutics worth $145,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 0.27% of the company’s stock.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.